Recent advances in systemic therapy. Advances in adjuvant systemic chemotherapy of early breast cancer
© BioMed Central Ltd 2009
Published: 19 March 2009
Skip to main content
© BioMed Central Ltd 2009
Published: 19 March 2009
Adjuvant treatment for early breast cancer is an evolving field. Since the advent of the initial cyclophosphamide, methotrexate and 5-fluorouracil (CMF) regimens, which reduced risk for recurrence and death, anthracyclines and subsequently taxanes were added to the cytotoxic armamentarium for use sequentially or in combination in the adjuvant setting. The efficacy and toxicity of each chemotherapy regimen must be viewed within the context of host co-morbidities and the specific biologic phenotype of the tumor. In the era of mammographic screening, small, node-negative breast cancer is the most frequent presentation of the disease. Patient selection for adjuvant chemotherapy has become a key issue. Traditional prognostic factors continue to be of value in determining the risk for relapse, but new and sophisticated genomic tools (such as Oncotype Dx® and Mammaprint®) are now available and may improve our ability to select patients. For those patients who do require adjuvant chemotherapy, the 'one size fits all' paradigm should never again feature in the treatment of early breast cancer, following the important insights yielded by biomarker research to identify those who will benefit the most from a particular drug. In this review we focus on some of the current controversies and potential future steps in adjuvant chemotherapy for treatment of early breast cancer.
Adjuvant systemic therapies were originally developed in an attempt to eradicate residual micrometastatic disease immediately after local control, in order to reduce the risk for cancer recurrence and death. From 10% to 30% of lymph node-negative breast cancer patients and 35% to 90% of lymph node-positive patients will eventually relapse with local therapy alone, because of occult micrometastatic disease . Randomized clinical trials (discussed below) have identified survival benefits from adjuvant therapy, with estimated reductions in the annual odds of death ranging from 8% to 28%. These benefits are maintained in patients outside the controlled conditions of clinical trials and have contributed, alongside screening programs, to an overall reduction in breast cancer mortality between 1975 and 2000 .
During the late 1960s the earliest clinical trials in the field began to evaluate the biologic concept of adjuvant chemotherapy in node-positive breast cancer, determining the effects of various chemotherapy regimens compared to observation after surgery to remove the primary tumor . These trials clearly demonstrated benefit from adjuvant chemotherapy in the subgroup of patients at high risk for recurrence [4, 5]. Chemotherapy combinations including cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) have exhibited long-term effectiveness in women with node-positive breast cancer . CMF-like regimens were able to reduce the annual odds of recurrence and death in operable breast cancer patients by 24% (± 3%) and 14% (± 4%), respectively .
Subsequently, during the late 1970s and early 1980s, anthracycline-containing combinations were tested in prospective randomized adjuvant trials. Overall, the anthracycline regimens (5-fluorouracil, doxorubicin, and cyclophosphamide [FAC]; 5-fluorouracil, epirubicin, and cyclophosphamide [FEC]; and doxorubicin and cyclophosphamide [AC], among others) are associated with reductions in the risk for recurrence of 11.2% (2P < 0.0001) and in the risk for death of 16% (2P < 0.00001), compared with CMF. Therefore, in absolute terms, the benefit is about 3% at 5 years and 4% at 10 years [8, 9]. The National Surgical Adjuvant Breast and Bowel Project (NSABP) group explored the differences between anthracycline and CMF regimens in two clinical trials, namely NSABP B-15 and B-23, showing that four cycles of AC were similar in terms of disease-free survival (DFS) and overall survival (OS) to six cycles of classical CMF [10, 11]. Other randomized studies and a meta-analysis clearly demonstrated that six cycles of an anthracycline-containing combination (FAC; FEC; cyclophosphamide, doxorubicin, and 5-fluorouracil; and cyclophosphamide, epirubicin, and 5-fluorouracil [CEF]) were superior to six cycles of CMF [7, 8, 12]. The optimal duration of the adjuvant therapy was also addressed in a French study (FASG-01) , which demonstrated that six cycles of adjuvant FEC were superior to three cycles of the same regimen in patients with operable breast cancer. Based on this growing body of evidence, during the 1990s consensus emerged that six cycles of a three-drug anthra-cycline-containing combination was the optimal adjuvant treatment for node-positive operable breast cancer, although the use of four-cycle AC and six-cycle CMF remained common practice in many institutions.
More recently, the taxanes have been added to the adjuvant armamentarium and are broadly used. In this review we address current prospects of adjuvant therapy, focusing on the advances in chemotherapy with taxanes and on treatment individualization; we also give attention to likely future developments involving taxanes intended to improve further outcomes in early-stage breast cancer.
The taxanes paclitaxel and docetaxel have a partial lack of cross-resistance with anthracyclines and were established in the 1990s as part of the standard treatment for metastatic breast cancer. Testing of these agents in the adjuvant setting was therefore also begun at that time.
Several phase III clinical trials have evaluated taxanes in the adjuvant setting. There are two generations of taxane clinical trials. In first-generation trials, a taxane-containing combination was compared with an anthracycline, nontaxane combination. In the second generation of trials, initiated once the taxanes became regarded as the 'gold standard', taxanes were included in all comparator arms.
First-generation phase III pure adjuvant studies of paclitaxel in breast cancer
Follow up (months)
CALGB 9344-INT 08 
AC × 4 versus AC × 4 → P × 4
65% versus 70% (5-year); HR = 0.83, P = 0.0023
77% versus 80% (5-year); HR = 0.82, P = 0.0064
NSABP B-28 
AC × 4 versus AC × 4 → P × 4
72% versus 76% (5-year); HR = 0.83, P = 0.006
85% versus 85% (5-year); HR = 0.93, P = 0.46
GEICAM 9906 
FEC × 6 versus FEC × 4 → wP × 8
72.1% versus 78.5% (5-year); HR = 0.74, P = 0.006
87.1% versus 89.9% (5-year); HR = 0.78, P = 0.109
HeCOG 10/97 
E × 4 → CMF × 4 versus E × 3 → P × 3 → CMF × 3a
68% versus 70% (5-year); P = 0.55
81% versus 84% (5-year); P = 0.38
NCIC CTG MA.21 
CEF versus AC → P versus dose-dense EC → P
90.1% (CEF) versus 85% (AC → P) versus 89.5% (dose-dense EC → P) (3-year RFS) AC → P versus CEF = HR = 1.49, P = 0.005 AC → P versus dose-dense EC → P = HR = 1.68, P = 0.0006 Dose-dense EC → P versus CEF = HR = 0.89, P = 0.46
CEF × 6 versus ET × 4
71% versus 70% (5-year); P = 0.8
89% versus 88% (5-year); P = NS
First-generation phase III studies of adjuvant docetaxel in breast cancer
Follow up (months)
FAC × 6 versus TAC × 6
68% versus 75% (5-year); HR = 0.72, P = 0.001
81% versus 87% (5-year); HR = 0.70, P = 0.008
FEC × 6 versus FEC × 3 → D × 3
73% versus 78% (5-year); HR = 0.82, P = 0.012
87% versus 91% (5-year); HR = 0.73, P = 0.017
ECOG 2197 
AC × 4 versus AD × 4
85% versus 85% (5-year); HR = 1.03, P = 0.78
91% versus 92% (5-year); HR = 1.06, P = 0.62
AC × 4 versus DC × 4
75% versus 81% (7-year); HR = 0.74, P = 0.033
82% versus 87% (7-year); HR = 0.69, P = 0.032
BIG 02-98 
A × 4 → CMF × 3 versus AC × 4 → CMF × 3 versus A × 3 → D × 3 → CMF × 3 versus AD × 4 → CMF × 3
D versus non-D = HR = 0.86, P = 0.051 Sequential D versus A-CMF = 78% versus 73% (5-year); HR = 0.79, P = 0.035 Concurrent AD versus AC-CMF = 74% versus 72% (5-year); HR = 0.93, P = 0.48 (NS)
TAXIT 216 
E × 4 → CMF × 4 versus E × 4 → D × 4 → CMF × 4
HR = 0.79, P = 0.0576
HR = 0.72, P = 0.0797
FEC × 8 or E × 4 → CMF × 4 versus FEC × 4 → D × 4
74% versus 75% (4-year); HR = 0.97 (NS)
82% versus 82% (4-year); HR = 0.98 (NS)
GEICAM 9805 
FAC × 6 versus TAC × 6
86% versus 91% (5-year); HR = 0.66, P = 0.02
95% versus 97% (5-year); HR = 0.72, P = 0.27
Mavroudis et al. 
FEC × 6 versus D × 4 → EC × 4
69% versus 75% (5-year); P = 0.029
WSG/AGO AM02 
FEC × 6 versus EC × 4 → D × 4
85.8% versus 90.2% (5-year); HR = 1.51, P = 0.009
92.6% versus 94.8% (5-year); HR = 1.59, P = 0.04
The trials discussed here are summarized in Table 1.
The first reported taxane study, the 9344-INT 08 trial , was conducted by the Cancer and Leukemia Group B (CALGB). Conducted in pre- and postmenopausal women with node-positive breast cancer, the study aimed to determine whether the benefits of four cycles of conventional AC could be improved upon either by doxorubicin dose escalation or by adding paclitaxel. A 3 × 2 factorial design was used to address both questions in one trial. Patients were randomly assigned to receive doxorubicin at one of three different dosages (60, 75, or 90 mg/m2) in combination with a fixed dose of cyclophosphamide (600 mg/m2), and then to receive or not receive four courses of paclitaxel (175 mg/m2 every 3 weeks). After a median follow up of 69 months, no significant reduction in relation to doxorubicin dose was identified in the hazard of recurrence or of death. However, the addition of paclitaxel to AC led to a 17% reduction in the risk for recurrence (P = 0.0023) and up to an 18% reduction in the risk for death (P = 0.0064). The main concern with these data is that the superiority of the taxane-containing regimen could partly be attributed to the more protracted therapy in this arm (3 versus 6 months), as opposed to a direct effect of the taxane therapy.
With a very similar design, the NSABP B-28 trial  added four cycles of paclitaxel at a higher dose (225 mg/m2 every 3 weeks) to four cycles of AC (60/600 mg/m2) in a sequential schedule, and administered adjuvant tamoxifen to all hormone receptor-positive patients and those older than 50 years, concurrent with chemotherapy. The addition of paclitaxel conferred a reduction in the risk for recurrence of 17% (P = 0.006) over that in patients treated with four cycles of AC. Analysis of OS, however, did not reveal any statistically significant differences between arms.
On the European side, the Grupo Español para la Investigación del Cáncer de Mama (GEICAM) recently reported the results of the 9906 trial , which had a median follow-up period of 66 months. Patients with node-positive operable breast cancer were randomized after surgery to receive six cycles of FEC (fluorouracil 600 mg/m2, epirubicin 90 mg/m2, and cyclophosphamide 600 mg/m2 on day 1 every 3 weeks) or four cycles of the same FEC regimen followed by 8 weeks of administration of paclitaxel (100 mg/m2 per week). Therefore, the duration of adjuvant treatment in both arms was very similar. After adjustment for other variables, FEC plus paclitaxel significantly reduced the risk for relapse by 23% compared with FEC, and the difference in DFS between the two arms was related to the greater number of distant breast cancer relapses in the FEC group. The analysis of OS identified a trend in favor of the paclitaxel arm, but the difference was not statistically significant at this point in the follow up (P = 0.109).
The Hellenic Cooperative Oncology Group trial HE 10/97  compared three cycles of epirubicin (110 mg/m2) followed by three cycles of paclitaxel (250 mg/m2) and three cycles of intensified CMF (cyclophosphamide 840 mg/m2, methotrexate 57 mg/m2, and 5-fluorouracil 840 mg/m2) versus four cycles of epirubicin every 2 weeks followed by four cycles of intensified CMF. The study identified a trend toward better survival in the taxane-containing arms, albeit without statistical significance. However, the study was under-powered to show small but clinically relevant differences.
More recently other two clinical trials have been reported in abstract form. The National Cancer Institute of Canada Clinical Trials Group MA.21 study, reported by Burnell and coworkers , tested the hypothesis that the addition of 3 months of paclitaxel after dose-dense epirubicin and cyclophosphamide (EC) chemotherapy would be superior to CEF alone or AC followed by paclitaxel. AC followed by paclitaxel, although less toxic, was inferior to the other arms in terms of recurrence-free survival, but it was still too early to detect any differences between CEF and dose-dense EC plus paclitaxel.
The most recently presented trial is a phase III study conducted by the Gruppo Oncologico Nord Ovest and Mammella Intergruppo, namely the GONO-MIG-5 study . The study compared CEF (cyclophosphamide 600 mg/m2, epirubicin 60 mg/m2, and 5-fluorouracil 600 mg/m2 given every 3 weeks for six cycles) versus EP (epirubicin 90 mg/m2 and paclitaxel 175 mg/m2 3-hour infusion given every 3 weeks for four cycles). No significant differences in DFS or OS were observed.
The trials discussed here are summarized in Table 2.
Chronologically, the first report of docetaxel administered concurrently with anthracyclines comes from the Breast Cancer International Research Group (BCIRG)-001, in the form of their TAX316 trial . This study randomly assigned women with node-positive breast cancer to six cycles of TAC (docetaxel 75 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2) or FAC (fluorouracil 500 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 500 mg/m2) every 3 weeks. TAC was associated with a statistically significant reduction in the risk for relapse and death (28% and 30%, respectively) relative to FAC. The reduction in the risk for relapse did not appear to be driven by nodal status or by hormone receptor or human epidermal growth factor receptor (HER)2 status. In terms of toxicity, febrile neutropenia and asthenia were the main side effects of TAC.
Shortly after the BCIRG-001 trial was reported, another French study, the Federation Nationale des Centres de Lutte Contre le Cancer PACS-01 trial , noted similar results supporting the use of sequential docetaxel in early breast cancer. Node-positive breast cancer patients were assigned to receive FEC (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2) for six cycles or the same regimen of FEC for three cycles followed by docetaxel 100 mg/m2 every 3 weeks for another three cycles. The multivariate analysis adjusting for prognostic factors identified a statistically significant reduction in the relative risk for relapse with FEC plus docetaxel (18%). There was a statistically significant reduction in risk for death as well (27%).
The Eastern Cooperative Oncology Group 2197 trial  randomized both node-positive and high-risk node-negative breast cancer patients to receive four cycles of AC or four cycles of AD (doxorubicin 60 mg/m2 plus docetaxel 60 mg/m2). Recently communicated results, with a median of 79.5 months of follow up, revealed no differences in DFS or OS. These negative results suggest either that the low dose of docetaxel used in the combination (60 mg/m2) or that the concurrent administration in a short course of AC are not the most effective ways to use docetaxel in the adjuvant setting.
The US Oncology Network (USO) 9735 trial [23, 24] is unique because it compared four cycles of AC versus four cycles of a taxane-containing, non-anthracycline regimen (docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 [TC]). Both node-positive and node-negative patients were included in the trial. Both DFS and OS were statistically significantly improved with TC. However, TC produced more myalgia, arthralgia, edema and febrile neutropenia, whereas more nausea and vomiting as well as one incident of congestive heart failure were the main secondary effects in the AC arm. In addition, TC was well tolerated in older women, without excessive toxicity in comparison with their younger counterparts.
The Breast International Group 02-98 trial  compared four treatment arms = a sequential control (four cycles of doxorubicin at 75 mg/m2, followed by three cycles of CMF); a concurrent control arm (four cycles of doxorubicin at 60 mg/m2 plus cyclophosphamide at 600 mg/m2, followed by three cycles of CMF); a sequential docetaxel arm (three cycles of doxorubicin at 75 mg/m2, followed by three cycles of docetaxel at 100 mg/m2, followed by three cycles of CMF); and a concurrent docetaxel arm (four cycles of doxorubicin at 50 mg/m2 plus docetaxel at 75 mg/m2 followed by three cycles of CMF). The analysis was performed after a median follow up of at least 5 years but with less than two-thirds of the number of DFS events originally planned, which limited the statistical power to answer definitively the originally planned questions. The primary comparison evaluated the incorporation of docetaxel, regardless of its schedule of administration, into anthracycline-based adjuvant chemotherapy, and it resulted in improved DFS of borderline statistical significance (hazard ratio [HR] of a DFS event of 0.86). Secondary comparisons found differences in efficacy possibly related to schedule of administration of chemotherapy. Thus, DFS was significantly better in the sequential docetaxel arm than in the sequential control arm (HR of a DFS event was 0.79), but DFS was no different in the concurrent docetaxel arm and in the concurrent control (HR of a DFS event was 0.93). When the two docetaxel arms were compared, DFS was better in the sequential docetaxel arm (HR of a DFS event was 0.83).
In the TAXIT 216 trial , node-positive breast cancer patients were randomly assigned either to epirubicin (120 mg/m2) for four cycles followed by CMF for four cycles (considered the standard treatment in Italy during the late 1990s) or to sequential docetaxel (100 mg/m2) for four cycles after four cycles of epirubicin and before four cycles of CMF. With a median follow-up period of 53.6 months, there was a tendency toward a benefit for the docetaxel-containing arm in terms of DFS (21% reduction in the risk for relapse, which was of borderline statistical significance).
The Taxotere as Adjuvant Chemotherapy trial  is the largest first-generation taxane-based adjuvant trial conducted to date. It compared four cycles of FE60C (fluorouracil 600 mg/m2, epirubicin 60 mg/m2, and cyclophosphamide 600 mg/m2 every 3 weeks) followed by four cycles of docetaxel (100 mg/m2) versus a standard treatment (either 2 eight cycles of FE60C or four cycles of epirubicin 100 mg/m followed by four cycles of CMF, at investigators' discretion). No differences in DFS or OS between experimental and standard arms were observed.
The Taxotere as Adjuvant Chemotherapy trial included both node-positive and high-risk node-negative patients, but the GEICAM 9805 trial  is the first taxane-based study that exclusively enrolled women with node-negative early-stage breast cancer at high risk for recurrence. As a complementary study to that conducted by BCIRG 001, GEICAM 9805 tested the same treatment arms but in a different population. TAC produced significantly more hematologic toxicity than did FAC, although primary prophylaxis with granulocyte colony-stimulating factor reduced the rate of neutropenic fever. A significant improvement in 5-year DFS was demonstrated in the TAC over the FAC arm, with 91% and 86% patients, respectively, alive and disease free. The OS data, although still immature, showed a nonsignificant 5-year OS of 97% for TAC and 95% for FAC.
Mavroudis and coworkers , from the Hellenic Oncology Research Group, presented data from another phase III study that compared the sequential administration of docetaxel (four cycles of 100 mg/m2) followed by EC versus FE75C (fluorouracil 700 mg/m2, epirubicin 75 mg/m2, and cyclophosphamide 700 mg/m2 every 3 weeks) as adjuvant chemotherapy in node-positive breast cancer. The docetaxel-containing treatment significantly improved the recurrence-free survival, but it was more toxic than FEC. The West German Study Group has also reported the results of the randomized intergroup phase III trial comparing EC followed by docetaxel versus FE100C (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2 every 3 weeks) in patients with intermediate-risk breast cancer. The 5-year OS rate was significantly higher with EC followed by docetaxel (95%) than for FEC (92.6%), suggesting the consideration of the sequential regimen in patients with one to three involved lymph nodes, even in hormone receptor-positive disease .
Second-generation phase III studies of adjuvant taxane therapy in breast cancer
Follow up (months)
A × 4 → P × 4 → C × 4 all q3w (conventional interval, sequential) versus A × 4 → P × 4 → C × 4 all q2w with filgrastim (dose-dense, sequential) versus AC × 4 → P × 4 all q3w (conventional interval, concurrent) versus AC × 4 → P × 4 all q2w with filgrastim (dose-dense, concurrent)
Dose-dense versus conventional interval = 82% versus 75% (4-year); HR = 0.74, P = 0.010 Concurrent versus sequential administration = HR = 0.93, P = 0.58 (NS)
Dose-dense versus conventional interval = 92% versus 90% (3-year); HR = 0.69, P = 0.013 Concurrent versus sequential administration = HR = 0.89, P = 0.48 (NS)
ECOG E1199 
AC × 4 → P × 4 all q3w (1) versus AC × 4 → P × 12 w (2) versus AC × 4 → D × 4 all q3w (3) versus AC × 4 → D × 12w (4)
76.9% (1) versus 81.5% (2) versus 81.2% (3) versus 77.6% (4; 5-year) Compared with standard (P q3w) = HR = 1.27, P = 0.006 (2); HR = 1.23, P = 0.02 (3); HR = 1.09, P = 0.29 (4)
86.5% (1) versus 89.7% (2) versus 87.3% (3) versus 86.2% (4) (5-year) Compared with standard (P q3w) = HR = 1.32, P = 0.01 (2); HR = 1.13, P = 0.25 (3); HR = 1.02, P = 0.80 (4)
EC → P × 4 versus EC → GP × 4
HR = 1.0; P = 0.96
HR = 1.1; P = 0.35
NSABP B-30 
AC × 4 → D × 4 versus AD × 4 versus ACD × 4
AC → D versus ACD = HR = 0.83, P = 0.006 AC → D versus AD = HR = 0.80, P = 0.001 ACD versus AD = HR = 0.96, P = 0.58
AC → D versus ACD = HR = 0.86, P = 0.086 AC → D versus AD = HR = 0.83, P = 0.034 ACD versus AD = HR = 0.96, P = 0.67
ACD × 6 versus AC × 4 → D100 × 4
78.9% versus 78.6% (5-year); HR = 1.002, P = 0.98
88.1% versus 88.9% (5-year); HR = 0.91, P = 0.37
The earliest of these second-generation trials was the CALBG 9741 trial . It was designed to test two hypotheses = the first was that dose-dense administration of chemotherapy was superior to conventional, every 3 weeks administration; and the second was that sequential, full-drug dosage was superior to combination chemotherapy. Node-positive breast cancer patients were assigned to one of the four possible treatment arms, consisting of sequential chemotherapy using doxorubicin, cyclophosphamide and paclitaxel, or concurrent doxorubicin and cyclophosphamide followed by paclitaxel at 14-day (with growth factor support) versus 21-day intervals in a 2 × 2 factorial design. Dose-dense chemotherapy was superior to conventional scheduling, but there was no significant difference between sequential and concurrent administration schedules. These data were consistent with one of the underlying hypotheses (namely that dose density could increase efficacy with a reasonable toxicity profile) but not the other (that sequential, full-dose therapy is superior to combination chemotherapy).
Other second-generation initiatives helped to shed light on the best taxane and the best schedule of administration of taxanes as well. The Southwest Oncology Group/Eastern Cooperative Oncology Group E1199 trial  included 4,950 node-positive or high-risk node-negative early breast cancer patients and randomly assigned them to one of the four treatment arms in a factorial design. All patients received AC for four cycles followed by taxane treatment, either docetaxel or paclitaxel, for 12 weeks in a weekly schedule (80 mg/m2 paclitaxel and 35 mg/m2 docetaxel) or every 3 weeks for four cycles (175 mg/m2 paclitaxel and 100 mg/m2 docetaxel). The primary end-points of the study were docetaxel versus paclitaxel efficacy and weekly versus every 3 weeks schedule. No significant differences in efficacy were found in the primary analysis (paclitaxel versus docetaxel, and weekly versus every 3 weeks schedule). This appears to have been due to the fact that paclitaxel performed better weekly, whereas docetaxel was more efficacious when administered every 3 weeks. As a secondary analysis, there was significantly better DFS in the group receiving weekly paclitaxel and in the group receiving docetaxel every 3 weeks, as compared with the group receiving paclitaxel every 3 weeks (considered as standard).
Besides the last two trials discussed above, the results from the Cancer Research UK tAnGo phase III study  were recently presented. This is the first trial to test whether the addition of further chemotherapy agents to anthracycline and taxane-containing regimens could be useful in the adjuvant setting. tAnGo compared EC-GP (four cycles of epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 every 3 weeks, followed by four cycles of paclitaxel 175 mg/m2 on day 1 and gemcitabine 1,250 mg/m2 on days 1 and 8 every 3 weeks) versus four cycles of EC followed by four cycles of paclitaxel 175 mg/m2. No significant differences in DFS or OS were observed between treatments.
At the 31st San Antonio Breast Cancer Symposium, data on two clinical trials exploring different combinations of taxanes were also reported. The NSABP B-30  compared three different regimens containing doxorubicin, docetaxel, and cyclophosphamide in women with operable, node-positive breast cancer (four cycles of AC followed by four cycles of docetaxel; four cycles of AD; and four cycles of TAC). According to the primary end-point, AC followed by docetaxel was marginally superior to four cycles of TAC (HR = 0.86; P = 0.086) and superior to four cycles of AD (HR = 0.83; P = 0.034) in terms of OS. Also, AC followed by docetaxel was superior to four cycles of TAC (HR = 0.83; P = 0.006) and of AD (HR = 0.80; P = 0.001) in terms of DFS. Furthermore, there were no treatment interactions between baseline nodal, estrogen receptor (ER), or menopausal status and outcome. The main efficacy analysis of BCIRG 005  was also presented. This phase III randomized trial compared TAC versus AC followed by docetaxel in women with normal HER2 and axillary lymph node-positive early breast cancer. In terms of the primary end-point, namely DFS, adjuvant TAC was equivalent to AC followed by docetaxel, despite the higher dose intensity of each of the three agents in the latter regimen and the eight cycles of treatment. From the toxicity standpoint, TAC was associated with more febrile neutropenia and granulocyte colony-stimulating factor use and less sensory neuropathy, nail change, and myalgia.
Overview of the main ongoing or closed but still not reported clinical trials that involve taxanes
Patient characteristics and end-points
Trials not recruiting or completed
AC × 4 → D100 × 4 versus AC × 4 → D75X × 4
1,810 node-positive and high-risk node-negative patients
ACD × 6 versus AC × 4 (q2w) → P × 4 (q2w) versus AC × 4 (q2w) → PG × 4 (q2w)
4,800 node-positive patients; DFS (primary); OS, recurrence and distant recurrence-free interval and toxicity (secondary)
FEC × 4 (q2w) → D × 4 (q2w) versus FEC × 4 (q2w) → P × 4 (q2w)
478 node-positive patients; DFS (primary); OS, recurrence rate, toxicity and QoL (secondary)
EC × 4 → D × 4 versus ED × 4 → X × 4
1,382 node-positive patients; DFS (primary); OS, toxicity, QoL, SNP predictors and molecular markers (secondary)
FAC × 6 versus FAC × 4 → P × 8w
1,920 high risk node-negative patients; DFS (primary); OS, toxicity, QoL and prognostic gene profile (2)
Trials actively recruiting
AC × 4 (q2w) versus AC × 6 (q2w) versus P × 4 (q2w) versus P × 6 (q2w)
4,646 with 0 to 3 positive nodes patients; DFS (primary); OS, local control, time to distant metastasis, toxicity, amenorrhea, MDR1 haplotype effect, CYP polymorphism effect
EF (d1, d8) C (oral d1–14) × 6 (q4w) versus EC (d1, d21, d42, d63) → D (d84, d105, d126,147)
446 node-positive patients; time to progression (primary); OS, toxicity and QoL (secondary)
AC × 6 (q2w) → P × 6 (q2w) versus AC × 6 (q2w) → P × 12(w) versus AC × 15 (Aw, C oral d1–7) → P × 6 (q2w) versus AC × 15 (Aw, C oral d1–7) → P × 12(w)
4,500 node-positive and high-risk node-negative patients; DFS (primary); OS, toxicity and prognostic markers (secondary)
D75 × 4 → E90 × 4 versus E75D75 × 6
724 high-risk node-negative patients; DF interval (primary); OS and safety (secondary)
TAC × 6 versus TC × 6
HER2 negative and node-positive and high-risk node-negative patients; DFS (primary)
The magnitude of the benefit from including taxanes in the adjuvant treatment of early breast cancer has been investigated in several meta-analyses.
A pooled analysis including 15,500 patients, from nine trials [14, 15, 17, 20, 21, 23, 36–38], was reported by Bria and coworkers . Significant differences in favor of taxanes were seen in DFS in the overall population (relative risk [RR] = 0.86, P < 0.00001) and lymph node-positive population (RR = 0.84, P < 0.0001), and in OS in both populations (RR = 0.87, P < 0.0001, and RR = 0.84, P < 0.0001, respectively). The absolute benefits in DFS and OS in favor of taxanes ranged from 3.3% to 4.6% and from 2.0% to 2.8%, respectively. Even restricting the analysis to the lymph node-positive patients, the absolute gains in DFS and OS were 4.3% and 2.8%, and the benefit was observed regardless of whether the sequential or concomitant approach was investigated. The number of patients needed to treat for a single beneficial patient ranged from 23 to 31 for DFS and from 36 to 50 for OS.
Subsequently, and with more mature survival data available, the Cochrane Collaboration  selected 12 studies [14–17, 20, 21, 23, 25, 26, 37, 38, 41], including more than 18,000 women and a median follow-up of 60.4 months. The HR was 0.81 (P < 0.00001) both for DFS and OS favoring taxane regimens, with no statistical heterogeneity for either survival end-point. This review was not able to identify a subgroup of patients who benefit more or less from taxanes, and no conclusions were drawn with respect to dosage and scheduling.
Taxane-containing adjuvant trials were included in the most recent, 2005 to 2006 updated version of the Early Breast Cancer Trialists' Collaborative Group overview presented by Peto . The recurrence rate ratio of taxane versus anthracycline in 20,000 randomized women was 0.83 (2P < 0.00001). Stratifying women by age, in young women the recurrence rate ratio of taxane versus no taxane was 0.38 (2P < 0.00001) and the breast cancer mortality rate ratio was 0.46 (2P < 0.00001), whereas in older women the proportional risk reduction was 0.52 (2P < 0.00001) in terms of recurrence rate and 0.66 (P = 0.00002) in terms of mortality. These data emphasize the role played by taxanes as new drugs to be included in the adjuvant treatment strategy of early breast cancer.
The largest meta-analysis reported thus far is that conducted by De Laurentiis and coworkers . It included 13 studies [14–17, 20, 21, 25, 26, 36–38, 43, 44] and as many as 22,903 patients. The pooled HR estimated was 0.83 (P < 0.00001) for DFS and 0.85 (P < 0.00001) for OS. Risk reduction was not influenced by the type of taxane (paclitaxel = HR = 0.83, P = 0.0004; and docetaxel = HR = 0.87, P = 0.003), by ER expression (ER-positive = HR = 0.83, P < 0.00001; and ER-negative = HR = 0.79; P < 0.00001), by the number of axillary metastases (one to three nodes = HR = 0.71, P < 0.0001; and four nodes or more = HR = 0.75, P = 0.0001), or by age/menopausal status. Taxane administration resulted in absolute improvements in 5-year DFS/OS of 5% and 3%, respectively, which is comparable to the reduction obtained with anthracyclines and reported in the Early Breast Cancer Trialists' Collaborative Group meta-analysis , which established taxanes' gold-standard status in the adjuvant setting.
The identification of patients who do not need or are unlikely to benefit from adjuvant chemotherapy is currently a relevant problem, because small, node-negative tumors are the usual form of presentation of the disease in the era of mammographic screening. Furthermore, there is also probably a relevant subset of patients with node-positive breast cancer (particularly those with high expression of ER) that does not benefit from any chemotherapy . However, the lack of prospective validation of this concept in the setting of an appropriate clinical trial renders its clinical application difficult.
In node-negative patients, tumor size, hormone receptor status, lymphovascular invasion, and histologic and nuclear grade have traditionally been the discriminating factors for selecting node-negative breast cancer patients for adjuvant chemotherapy. Adjuvant! , a program that estimates a patient's risk for recurrence with different therapeutic options based on classical clinical and pathological findings, is often used for the same purpose . Patients with a risk for relapse exceeding 10% (with or without hormonal therapy, depending on hormone receptor status) are often offered adjuvant chemotherapy. The St Gallen Consensus Conference  has also established successive classifications of risk for relapse based on clinical and pathologic features, including HER2 status in its last version. More recently, two genomic signatures, Oncotype Dx® (Genomic Health Inc., Redwood City, CA, USA) and Mammaprint® (Agendia BV, Amsterdam, The Netherlands), have been developed to select those patients with node-negative disease who are more likely to benefit from adjuvant chemotherapy. A detailed description of these tools is beyond the scope of this overview. Pending a final validation in the MINDACT (Microarray in Node Negative Disease May Avoid ChemoTherapy) and TAILORx (Trial Assigning IndividuaLized Options for Treatment [Rx]) trials [49, 50], the genomic fingerprints appear to predict recurrence in node-negative breast cancer patients (and perhaps in node-positive patients as well) more accurately than Adjuvant! or the classical prognostic factors.
Most adjuvant chemotherapy trials were performed in unselected patient populations or, more precisely, in populations selected according exclusively to anatomy (axillary status) or demographics (menopausal status) rather than tumor biology. Most of these trials did not stratify patients according to hormonal status, even though the relevance of this biologic factor was well known at the time when the trials were designed. This lack of forward thinking is unfortunate. We know that, overall, the taxane containing combinations are superior to anthracycline (nontaxane) containing combinations, and that the anthracyclines performed better than CMF. In general, however, this superiority is associated with more toxicity. Furthermore, the benefit of the newer combinations over the older ones is small (3% to 5% in absolute terms), and we cannot identify the subsets of patients who actually benefit from the new drugs. In other words, we need to treat 100 patients to benefit only three to five of them, while administering what is usually a more toxic treatment to the remaining 95 to 98 patients who do not derive any survival benefit.
Several attempts have been made to identify the population that actually benefits from anthracyclines versus CMF and taxanes versus anthracyclines, but all of them are based on retrospective subset analyses and meta-analyses.
Anthracyclines were considered the gold standard of adjuvant chemotherapy until the late 1990s. In absolute terms, the absolute DFS benefit conferred by anthracyclines compared with CMF is about 3% at 5 years and 4% at 10 years in meta-analyses [8, 9], although one can speculate that the benefit with anthracyclines is underestimated by the meta-analyses because of the inclusion of 'unfair' trials with asymmetric design (in particular, two large NSABP trials in which six cycles of CMF were compared with four cycles of AC, which identified no differences in outcome). However, the long-term, sometimes fatal side effects of anthracyclines, in particular cardiac toxicity and leukemias/myelodysplastic syndrome, can partly counter-balance these benefits. Anthracyclines can trigger a chronic, usually irreversible, dose-dependent cardio-myopathy (type I) by causing myocardial structural changes and cardiac tissue remodeling, the consequences of which may appear months or years after chemotherapy. Although a well recognized phenomenon, the real magnitude of the problem of severe anthracycline-induced cardiac toxicity is still a matter of debate. In randomized phase III clinical trials, the prevalence of grade 2 to 4 cardiac toxicity with anthra-cyclines was in the range 0.5% to 1.5%, although the follow up of these trials was less than 6 years. In the long term, anthracycline-induced cardiac damage could have relevant consequences, according to two population-based studies conducted in older patients [51, 52]. The cardiac toxicity of anthracyclines is increased when these drugs are followed by trastuzumab. In the trastuzumab adjuvant trials, the incidence of severe cardiac toxicity with anthracyclines followed by trastuzumab ranged from around 2% to 4% [53, 54]. Apart from cardiotoxicity, anthracyclines have other important long-term adverse effects, such as acute myeloid leukemia and myelodysplastic syndrome, which occur in around 0.5% of patients [55, 56].
Anthracycline use can be optimized in two ways = by selecting patients who are more likely to benefit from these drugs according to tumor biology, and by reducing the risk for irreversible side effects. The latter could be attempted by diminishing the total cumulative dose, selecting patients at very low cardiac risk (young women without cardiac risks), or introducing the newer liposomal formulations, which are clearly less cardiotoxic.
The selection of patients whose tumors are more likely to respond to anthracyclines is a field of currently intense investigation. Several retrospective analysis and a meta-analysis [57–59] have suggested that the improvement in DFS and OS with adjuvant anthracyclines over CMF in the phase III trials is restricted to patients whose tumors present with the HER2 alteration. Other similar studies, however, have found that the patients who actually benefit from adjuvant anthracyclines are those whose tumors have topo-isomerase II α amplification [58, 60]. A plausible explanation for this discrepancy is that most if not all topoisomerase II α amplifications are observed in tumors with concurrent HER2 amplification . Therefore, topoisomerase II α amplification and not HER2 amplification would be the real predictive factor. Regardless, the demonstration that the adjuvant administration of the new targeted anti-HER2 monoclonal antibody trastuzumab significantly improves DFS and OS in breast cancer patients whose tumors over-express HER2 [54, 61–64] will probably change the role of anthracyclines in the adjuvant setting.
Anthracyclines appear to be most effective in patients whose tumors have topoisomerase II α amplification (usually associated with HER2 amplification), and we now have newer, less toxic drugs that effectively target HER2-amplified tumors; the role of anthracyclines should therefore be revisited. Interestingly, support for this idea comes from the BCIRG 006 trial , which compared AC followed by docetaxel versus this same regimen plus trastuzumab and the non-anthracycline-containing combination THC (docetaxel, carbo-platin, and trastuzumab) as adjuvant therapy for operable breast tumors over-expressing HER2. A subgroup analysis showed that AC followed by docetaxel plus trastuzumab was not superior to THC in either subgroup of patients (topoisomerase II α amplified and nonamplified tumors). Statistically significant superiority of the two trastuzumab-containing arms over AC followed by docetaxel was observed in the group of patients whose tumors had amplification of HER2 but not of topoisomerase II α. In the subgroup of patients whose tumors had co-amplification of both genes, the three arms were similarly effective. If these data are maintained over time, then the role of anthracyclines in the adjuvant setting would be seriously challenged, because THC could be concluded to be similarly effective and is clearly less cardiotoxic than the anthracycline-containing combinations.
Regarding the taxanes, several attempts have been made to discover molecular factors that could predict response to these drugs. Unfortunately, none of the first-generation adjuvant taxane trials were designed to determine the effectiveness of taxanes in subgroups of patients with different tumor biomarkers, with only retrospective, unplanned analyses being available.
Subgroup analysis by hormone receptor status of the benefit from taxane-containing adjuvant chemotherapy regimens
HR (95% CI) for DFS
Number of patients
Stratification by hormone receptor status
Hormone receptor positive
Hormone receptor negative
AC × 4 versus AC × 4 → P × 4
NSABP B-28 
AC × 4 versus AC × 4 → P × 4
0.77 (0.65–0.92), P = 0.004
0.90 (0.72–1.12), P = 0.33
GEICAM 9906 
FEC × 6 versus FEC × 4 → wP × 8
0.79 (0.54–1.15), P = 0.216
0.76 (0.51–1.12), P = 0.163
E × 4 → CMF × 4 versus E × 3 → P × 3 → CMF × 3 (q2w)
E 2197 
AC × 4 versus AT × 4
0.99 (0.75–1.30), P = 0.96c
1.21 (0.92–1.59), P = 0.17c
USO 9735 
AC × 4 versus TC × 4
BIG 02-98 
A × 4 → CMF × 3 versus AC × 4 → CMF × 3 versus A × 3 → T × 3 → CMF × 3 versus AT × 4 → CMF × 3
D versus control = 0.86 (0.71–1.03) Sequential D versus sequential control = 0.79 (0.61–1.05)
D versus control = 0.89 (0.69–1.15) Sequential D versus sequential control = 0.80 (0.55–1.15)d
BCIRG 001 
FAC × 6 versus TAC × 6
PACS 01 
FEC × 6 versus FEC × 3 → T × 3
E 1199 
AC × 4 → P × 4 all q3w versus AC × 4 → P × 12w versus AC × 4 → D × 4 all q3w versus AC × 4 → D × 12w
1.31 (1.00–1.72), P = 0.05e
1.37 (0.98–1.93), P = 0.07e
The relationship between HER2 status and taxane efficacy has been explored in a few studies, which yielded conflicting conclusions. Hayes and coworkers, using tumor samples from patients of the CALBG-9344 trial , tried to determine whether HER2 expression identified patients who were likely to benefit from doses of doxorubicin above 60 mg/m2, the addition of paclitaxel after anthracyclines, or both. There was an interaction between HER2 positivity and benefit from paclitaxel addition, with an HR for recurrence of 0.59 (P = 0.01) regardless of ER status. However, these results were not confirmed by the GEICAM 9906 trial , in which no significant interaction was found between treatment with paclitaxel and HER2 status.
Other molecular markers that are more or less related to the mechanism of action or metabolism of taxanes (such as β-tubulin isotypes, protein tau, P-glycoprotein, and so on) and some genetic signatures have been proposed as predictors of taxane efficacy [69, 70]. These studies have a reduced power to detect clinically meaningful relationship because of the limited sample size and other methodological problems. None of these markers have been validated by large prospective clinical trials or meta-analysis, and therefore we are presently unable to select patients who may benefit from adjuvant taxanes based on molecular features.
Taxanes and trastuzumab have permanently entered the adjuvant setting, based on their consistently positive results in randomized clinical trials. The discussion of which is the best regimen or schedule, and new strategies to combine all of these tools is wide open. However, these new alternatives have challenged the established role of anthracyclines as the backbone of adjuvant treatment in early breast cancer. With a growing pool of active drugs, their tolerability and – more importantly – their long-term toxicity profiles come into focus when considerations turn to cure and preservation of quality of life.
A whole spectrum of targeted drugs is being or is about to be tested for use in early breast cancer, once they have demonstrated activity in advanced stages of the disease. Their ability to interfere with survival, proliferation, and angiogenesis or the motility, migration, and invasiveness processes of tumor cells could be even more relevant in this earlier phase of the natural history of breast cancer.
As the number of treatment options increases, the need to define a set of criteria to select those patients who will benefit from each treatment regimen or strategy becomes a priority. The appropriateness of clinical trial designs to address this issue is currently a major concern.
doxorubicin and cyclophosphamide
doxorubicin and docetaxel
Breast Cancer International Research Group
Cancer and Leukemia Group B
cyclophosphamide, epirubicin, and 5-fluorouracil
cyclophosphamide, methotrexate, and 5-fluo-rouracil
epirubicin and cyclophosphamide
5-fluorouracil, doxorubicin, and cyclophosphamide
5-fluorouracil, epirubicin, and cyclophosphamide
Grupo Español para la Investigación del Cáncer de Mama
human epidermal growth factor receptor
National Surgical Adjuvant Breast and Bowel Project
docetaxel, doxorubicin, and cyclophosphamide
docetaxel and cyclophosphamide
docetaxel, car-boplatin, and trastuzumab
US Oncology Network.